Steven E. Nissen

Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a)

Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk

Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial

Assessment of omega‐3 carboxylic acids in statin‐treated patients with high levels of triglycerides and low levels of high‐density lipoprotein cholesterol: Rationale and design of the STRENGTH trial

Effect of Evolocumab on Coronary Plaque Composition

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance

Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib

Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome

Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN

Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study

C-Reactive Protein, but not Low-Density Lipoprotein Cholesterol Levels, Associate With Coronary Atheroma Regression and Cardiovascular Events After Maximally Intensive Statin Therapy

Effect of Aliskiren on Progression of Coronary Disease in Patients With Prehypertension